MX2019010828A - Metodos para identificar la predisposicion al declive cognitivo y agentes para reducir o prevenir el declive cognitivo o para mejorar la capacidad cognitiva. - Google Patents

Metodos para identificar la predisposicion al declive cognitivo y agentes para reducir o prevenir el declive cognitivo o para mejorar la capacidad cognitiva.

Info

Publication number
MX2019010828A
MX2019010828A MX2019010828A MX2019010828A MX2019010828A MX 2019010828 A MX2019010828 A MX 2019010828A MX 2019010828 A MX2019010828 A MX 2019010828A MX 2019010828 A MX2019010828 A MX 2019010828A MX 2019010828 A MX2019010828 A MX 2019010828A
Authority
MX
Mexico
Prior art keywords
omega
vitamin
levels
homocystein
individuals
Prior art date
Application number
MX2019010828A
Other languages
English (en)
Inventor
Rieker Claus
Hudry-Labbe Julie
Boschat Corina
BOWMAN Gene
Antonius Johannes Schmitt Jeroen
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/074731 external-priority patent/WO2018060396A1/en
Priority claimed from EP17193916.8A external-priority patent/EP3388061A1/en
Priority claimed from PCT/EP2017/082148 external-priority patent/WO2018188771A1/en
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of MX2019010828A publication Critical patent/MX2019010828A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

Un método para identificar la predisposición al declive cognitivo en un sujeto, el método comprende determinar independientemente los niveles de: (a) ácidos grasos omega-3, y vitamina D o un metabolito de esta; (b) ácidos grasos omega-3, y homocisteína; (c) vitamina D o un metabolito de esta, y homocisteína; o (d) ácidos grasos omega-3, vitamina D o un metabolito de esta, y homocisteína, en una o más muestras obtenidas del sujeto.
MX2019010828A 2017-04-11 2018-04-05 Metodos para identificar la predisposicion al declive cognitivo y agentes para reducir o prevenir el declive cognitivo o para mejorar la capacidad cognitiva. MX2019010828A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762484119P 2017-04-11 2017-04-11
US201762484156P 2017-04-11 2017-04-11
PCT/EP2017/074731 WO2018060396A1 (en) 2016-09-29 2017-09-29 Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
EP17193916.8A EP3388061A1 (en) 2017-04-11 2017-09-29 Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
US201762580574P 2017-11-02 2017-11-02
PCT/EP2017/082148 WO2018188771A1 (en) 2017-04-11 2017-12-11 Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
PCT/EP2018/058701 WO2018189020A2 (en) 2017-04-11 2018-04-05 Methods for identifying pre-disposition to cognitive decline and agents for reducing or preventing cognitive decline, or improving cognitive ability

Publications (1)

Publication Number Publication Date
MX2019010828A true MX2019010828A (es) 2019-10-15

Family

ID=67682482

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010484A MX2019010484A (es) 2017-04-11 2017-12-11 Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos.
MX2019010828A MX2019010828A (es) 2017-04-11 2018-04-05 Metodos para identificar la predisposicion al declive cognitivo y agentes para reducir o prevenir el declive cognitivo o para mejorar la capacidad cognitiva.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019010484A MX2019010484A (es) 2017-04-11 2017-12-11 Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos.

Country Status (8)

Country Link
US (6) US20210128587A1 (es)
EP (3) EP3609490A1 (es)
JP (6) JP7270546B2 (es)
CN (3) CN110381935A (es)
AU (4) AU2017408873A1 (es)
BR (3) BR112019017949A2 (es)
CA (3) CA3054846A1 (es)
MX (2) MX2019010484A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010484A (es) * 2017-04-11 2019-10-17 Nestle Sa Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos.
CN113252806B (zh) * 2021-03-25 2023-08-29 嘉兴学院 S-腺苷同型半胱氨酸在制备用于诊断或治疗川崎病的产品中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
GB0016460D0 (en) * 2000-07-04 2000-08-23 Axis Shield Asa Assay
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US8017657B1 (en) * 2001-09-07 2011-09-13 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
WO2004075905A1 (ja) * 2003-02-26 2004-09-10 Kyowa Hakko Kogyo Co., Ltd. 筋肉増強剤および筋肉減衰の予防または治療剤
US20070078114A1 (en) * 2005-09-02 2007-04-05 Myriad Genetics, Incorporated Combination therapy for alzheimer's disease and other diseases
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
NZ599748A (en) 2007-06-26 2013-11-29 Nutricia Nv Improving memory in subjects with mini-mental state examination of 24-26
TR201807131T4 (tr) * 2007-10-04 2018-06-21 Nestec Sa Bilişsel işlevi iyileştirmek için kompozisyonlar ve yöntemler.
EP3058942B2 (en) * 2008-01-04 2023-03-22 Société des Produits Nestlé S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
AU2009326857B2 (en) 2008-12-09 2016-05-26 Stephanie Fryar-Williams Novel biomarkers
WO2010078504A1 (en) * 2008-12-31 2010-07-08 Nitromega Corp. Nutraceuticals containing nitro fatty acids
CN101897706A (zh) * 2009-05-27 2010-12-01 北京奥萨医药研究中心有限公司 含有叶酸和b族维生素的组合物及其用途
EP2440201A1 (en) * 2009-06-10 2012-04-18 Energy4life Ag Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
US8563609B2 (en) * 2010-05-13 2013-10-22 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
AU2011315532B2 (en) 2010-10-12 2015-02-05 Vifor Sa Novel omega-3 and omega-6 fatty acid compositions and uses thereof
EP2685987B1 (en) * 2011-03-18 2019-04-24 Nestec S.A. Compositions and methods useful for ameliorating age related maladies
AU2012331692B2 (en) * 2011-10-31 2017-03-02 N.V. Nutricia Composition for improving neuropsychological test battery score
AU2013299656C1 (en) * 2012-08-07 2017-06-22 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
FR3002044A1 (fr) * 2013-02-08 2014-08-15 Centre Nat Rech Scient Marqueur dyrk1a pour la maladie d'alzheimer
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
AU2014235034A1 (en) 2013-03-15 2015-10-01 Buck Institute For Research On Aging Improved cognitive supplements
EP2899543A1 (en) 2014-01-28 2015-07-29 Predemtec GmbH Biomarker and methods for early diagnosis of Alzheimer's disease
GB201405033D0 (en) * 2014-03-20 2014-05-07 Isis Innovation Combination therapy
ES2860427T3 (es) * 2015-06-22 2021-10-05 Nestle Sa Composiciones y métodos para mejorar la neurogénesis en animales
WO2017004436A2 (en) 2015-07-01 2017-01-05 The Regents Of The University Of California A therapeutic system comprising pharmaceuticals in combination with metabolic enhancement for neurodegeneration
US20180268940A1 (en) * 2015-09-25 2018-09-20 Buck Institute For Research On Aging Compositions and methods for specific biological cognitive functions in neurodegenerative diseases
AU2017270131B2 (en) * 2016-05-27 2023-03-09 Société des Produits Nestlé S.A. Nutritional composition for treating or preventing impaired mobility
AU2017336291B2 (en) * 2016-09-29 2023-01-12 Société des Produits Nestlé S.A. Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia
MX2019010484A (es) * 2017-04-11 2019-10-17 Nestle Sa Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos.

Also Published As

Publication number Publication date
JP2023030130A (ja) 2023-03-07
AU2018251094B2 (en) 2023-11-02
US20240041915A1 (en) 2024-02-08
AU2017408873A1 (en) 2019-08-29
EP3609487A1 (en) 2020-02-19
MX2019010484A (es) 2019-10-17
JP2020516864A (ja) 2020-06-11
EP3609491A2 (en) 2020-02-19
AU2018251094A1 (en) 2019-09-05
AU2018251092B2 (en) 2024-02-29
AU2018251092A1 (en) 2019-09-05
US20210263048A1 (en) 2021-08-26
EP3609490A1 (en) 2020-02-19
CN110381935A (zh) 2019-10-25
US20230310488A1 (en) 2023-10-05
US20200054665A1 (en) 2020-02-20
BR112019018729A2 (pt) 2020-04-07
JP7270547B2 (ja) 2023-05-10
JP2020516862A (ja) 2020-06-11
JP7434458B2 (ja) 2024-02-20
AU2024200882A1 (en) 2024-02-29
BR112019017949A2 (pt) 2020-05-19
US20230028607A1 (en) 2023-01-26
CN110475553A (zh) 2019-11-19
CA3054846A1 (en) 2018-10-18
CA3054869A1 (en) 2018-10-18
JP2022172152A (ja) 2022-11-15
BR112019020008A2 (pt) 2020-04-28
JP2020516586A (ja) 2020-06-11
CN110430873A (zh) 2019-11-08
JP7434459B2 (ja) 2024-02-20
JP2022166175A (ja) 2022-11-01
US20210128587A1 (en) 2021-05-06
JP7270546B2 (ja) 2023-05-10
CA3054864A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
EA201792389A1 (ru) Пцр в реальном времени для мультиплексной оптимизированной амплификации с несоответствиями (moma) и для оценки неклеточной днк
EA201991105A1 (ru) Методы оценки риска с использованием общей и специфической неклеточной днк
WO2016130704A3 (en) Methods and compositions for analyzing cellular components
MX368815B (es) Método y dispositivo para analizar relación social.
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
BR112017019774A2 (pt) uso de uma membrana capilar porosa para determinar a quantidade de produtos de am-plificação por círculo rolante
CL2018002548A1 (es) Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786)
PT110171A (pt) Método de treino da capacidade cognitiva com base emocional
BR112017004299A2 (pt) dispositivo e método de processamento de informação, e, programa.
MX2019010828A (es) Metodos para identificar la predisposicion al declive cognitivo y agentes para reducir o prevenir el declive cognitivo o para mejorar la capacidad cognitiva.
MX365713B (es) Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos.
EA201791766A1 (ru) Составы в виде милликапсул, содержащие полиненасыщенные свободные жирные кислоты
BR112016006383A2 (pt) método de extração de proteína
MX2017009752A (es) Adn huesped como biomarcador de la enfermedad de crohn.
BR112017013256A2 (pt) método de análise, portador de amostra em forma de disco e aplicação de um portador de amostra
WO2016196993A8 (en) Multi-mediator reagent formulations for use in electrochemical detection
MX2016007148A (es) Metodos de ensayo de beta-glucano.
WO2018189020A3 (en) METHODS OF IDENTIFYING PREDISPOSITION TO COGNITIVE DECLINE AND AGENTS FOR REDUCING OR PREVENTING COGNITIVE DECLINE, OR ENHANCING COGNITIVE CAPACITY
PH12018502207A1 (en) Methods of manufacturing nutritional formulations
MY178495A (en) Shuffle play method and device
PL410179A1 (pl) Sposób otrzymywania erytrytolu
DK3638109T3 (da) Fremgangsmåde til bestemmelse af koncentrationen af en analyt i fuldblod
GB2553736A (en) Method for identification of a deficient BRCA1 function
PL412364A1 (pl) Sposób otrzymywania erytrytolu